Search Results for: insurance

Is unproven stem cell therapy covered by insurance?

Does insurance cover stem cell therapy? Even at clinics? What about coverage from employers?

A common question I hear from readers of The Niche is some version of, “Is stem cell therapy covered by insurance?” Sometimes they also ask about Medicare coverage. To be clear, I’m talking about unproven stem cell “therapies” here. The type clinics sell. It’s not FDA approved so generally insurance companies and Medicare will not […]

Is unproven stem cell therapy covered by insurance? Read More »

Does insurance cover stem cell therapy at unproven clinics?

Does insurance cover stem cell therapy? Even at clinics? What about coverage from employers?

Stem cell injections at unproven clinics are expensive and unproven so a lot of patients have asked me if insurance covers stem cell therapy at clinics? Mostly the answer is “no”, but in rare cases there is some kind of coverage, mainly from employers that have inked some kind of deal with a stem cell

Does insurance cover stem cell therapy at unproven clinics? Read More »

Eight simple reasons not to get an unlicensed stem cell treatment: reason 1 is lost health insurance

Patients ask me all the time about stem cell treatments. Some are curious. Some have already had treatments. Others are very seriously considering a treatment, but haven’t done so yet. Some are open-minded. Some are not. Some are angry with me for my track record of criticizing for-profit, unlicensed clinics offering stem cell treatments. In

Eight simple reasons not to get an unlicensed stem cell treatment: reason 1 is lost health insurance Read More »

Q&A with Kyle Cetrulo of The Perinatal Stem Cell Society on the FDA, state laws, & more

Kyle Cetrulo, Perinatal Stem Cell Society

I was interested to see that an organization called The Perinatal Stem Cell Society seems to have been upbeat about the new Utah stem cell law. That law sets up a likely conflict with the FDA and federal law over stem cells. In a nutshell, Utah now says you can sell non-FDA-approved stem cells in

Q&A with Kyle Cetrulo of The Perinatal Stem Cell Society on the FDA, state laws, & more Read More »

Weekly reads: FDA OKs 2 gene therapies for sickle cell, new Paolo Macchiarini series, Fujifilm

Marie Tornyenu, Casgevy gene therapies for sickle cell

The big news broke Friday that the FDA approved two new gene therapies for sickle cell disease. While the approvals were expected and the actual use of these treatments will be complex on several levels, this is a historic development. 2 FDA-approved gene therapies for sickle cell Friday’s news follows on recent UK approval for

Weekly reads: FDA OKs 2 gene therapies for sickle cell, new Paolo Macchiarini series, Fujifilm Read More »

Stem cell therapy cost in 2024: data & analysis

stem cell therapy cost

How much does stem cell therapy cost in 2024? How have prices changed? To authoritatively answer these questions now we need data from the present and past along with expert perspectives. Some surprises come up in this new analysis. In this article Intro  | Stem Cell Therapy Cost: $10,000-$20,000 | Why do stem cells cost so much?

Stem cell therapy cost in 2024: data & analysis Read More »

Does Medicare cover stem cell therapy? Mostly no & it’s poised to recoup tens of millions

Regenative labs, does Medicare cover stem cell therapy?

Does Medicare cover stem cell therapy? Readers of The Niche have regularly asked this question. They’re curious about insurance coverage too. The answer is “no” in almost every case, with some notable exceptions I’ll get to at the end of the post. Still, clinics appear to have already been charging Medicare for what collectively adds

Does Medicare cover stem cell therapy? Mostly no & it’s poised to recoup tens of millions Read More »

Review of ExoFlo paper used to push Direct Biologics IND inside FDA finds red flags

ExoFlo from Direct Biologics

I wrote recently about how political pressure on FDA Commissioner Stephen Hahn in 2020 may have helped the Texas firm Direct Biologics move their product ExoFlo forward inside the agency. Today I analyze the ExoFlo Phase I clinical trial paper used in that push on Hahn to get the firm the IND for a Phase II

Review of ExoFlo paper used to push Direct Biologics IND inside FDA finds red flags Read More »

ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes

Doug Melton, Vertex, ViaCyte

When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are

ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »